Search

Search Constraints

You searched for: Author/Creator Ferracane, Concetta

Search Results

1. A propensity score weighted comparison of Vedolizumab, Adalimumab, and Golimumab in patients with ulcerative colitis. Issue 12 (December 2020)

2. A Propensity Score-matched Comparison of Infliximab and Adalimumab in Tumour Necrosis Factor-α Inhibitor-naïve and Non-naïve Patients With Crohn's Disease: Real-Life Data From the Sicilian Network for Inflammatory Bowel Disease. (6th October 2018)

3. A real life comparison of the effectiveness of adalimumab and golimumab in moderate-to-severe ulcerative colitis, supported by propensity score analysis. Issue 12 (December 2018)

4. Effectiveness of Ustekinumab on Crohn's Disease Associated Spondyloarthropathy: Real-World Data from the Sicilian Network for Inflammatory Bowel Diseases (SN-IBD). (1st November 2020)

5. SPOSAB ABP 501 - A SICILIAN PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS WITH INFLAMMATORY BOWEL DISEASE TREATED WITH ADALIMUMAB BIOSIMILAR ABP 501. (21st January 2021)

6. SPOSAB ABP 501: A Sicilian Prospective Observational Study of Patients with Inflammatory Bowel Disease Treated with Adalimumab Biosimilar ABP 501. Issue 11 (3rd July 2021)

7. The real-world effectiveness of vedolizumab on intestinal and articular outcomes in inflammatory bowel diseases. Issue 7 (July 2018)

8. Ustekinumab in Crohn's disease: Real‐world outcomes from the Sicilian network for inflammatory bowel diseases. Issue 3 (2nd February 2021)

9. Vedolizumab may be an effective option for the treatment of postoperative recurrence of Crohn's disease. Issue 5 (May 2022)